Omalizumab in children with severe allergic disease: a case series.
Omalizumab. Asthma. Food allergy. Immunoglobulin E. pediatrics
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
14 Jan 2019
14 Jan 2019
Historique:
received:
01
10
2018
accepted:
03
01
2019
entrez:
16
1
2019
pubmed:
16
1
2019
medline:
22
5
2019
Statut:
epublish
Résumé
Currently, severe allergic asthma and food allergy in children represent an important public health problem with medical, psychosocial and economic impacts. Omalizumab is a humanized monoclonal anti-IgE antibody, approved for refractory allergic asthma and chronic urticaria. It has been widely used in clinical practice as add-on therapy in patients with severe uncontrolled allergic asthma. In recent years there has seen the emergence of an allergic epidemic with increasing food allergy, which represents the main cause of anaphylaxis in children. The standard of care for food allergy is strictly dietary allergen avoidance and emergency treatment, but recent clinical trials have suggested that omalizumab may have a role to play as an adjuvant to oral immunotherapy (OIT). We present a case series of patients treated at our institution with omalizumab for severe allergic asthma and food allergy. Patients received omalizumab according to a standard reference nomogram after failing standard therapies. In children with comorbid severe food allergy, omalizumab was administered in conjunction with an oral immunotherapy protocol. Omalizumab was effective in controlling symptoms of allergic asthma, allergic rhinitis and rhinosinusitis, but not eosinophilic esophagitis, while aiding successful oral desensitization of comorbid severe food allergies. Omalizumab appears to be an excellent therapeutic option in children with inadequately controlled severe allergic asthma, allergic rhinitis and rhinosinusitis, with or without food allergy.
Sections du résumé
BACKGROUND
BACKGROUND
Currently, severe allergic asthma and food allergy in children represent an important public health problem with medical, psychosocial and economic impacts. Omalizumab is a humanized monoclonal anti-IgE antibody, approved for refractory allergic asthma and chronic urticaria. It has been widely used in clinical practice as add-on therapy in patients with severe uncontrolled allergic asthma. In recent years there has seen the emergence of an allergic epidemic with increasing food allergy, which represents the main cause of anaphylaxis in children. The standard of care for food allergy is strictly dietary allergen avoidance and emergency treatment, but recent clinical trials have suggested that omalizumab may have a role to play as an adjuvant to oral immunotherapy (OIT). We present a case series of patients treated at our institution with omalizumab for severe allergic asthma and food allergy.
METHODS
METHODS
Patients received omalizumab according to a standard reference nomogram after failing standard therapies. In children with comorbid severe food allergy, omalizumab was administered in conjunction with an oral immunotherapy protocol.
RESULTS
RESULTS
Omalizumab was effective in controlling symptoms of allergic asthma, allergic rhinitis and rhinosinusitis, but not eosinophilic esophagitis, while aiding successful oral desensitization of comorbid severe food allergies.
CONCLUSIONS
CONCLUSIONS
Omalizumab appears to be an excellent therapeutic option in children with inadequately controlled severe allergic asthma, allergic rhinitis and rhinosinusitis, with or without food allergy.
Identifiants
pubmed: 30642367
doi: 10.1186/s13052-019-0602-5
pii: 10.1186/s13052-019-0602-5
pmc: PMC6332555
doi:
Substances chimiques
Anti-Allergic Agents
0
Omalizumab
2P471X1Z11
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13Références
Pediatrics. 2001 Aug;108(2):E36
pubmed: 11483846
Pediatrics. 2002 Nov;110(5):e55
pubmed: 12415061
Ann Allergy Asthma Immunol. 2003 Aug;91(2):182-8
pubmed: 12952113
J Allergy Clin Immunol. 2005 Mar;115(3):459-65
pubmed: 15753888
J Allergy Clin Immunol. 2008 Feb;121(2):343-7
pubmed: 18158176
Clin Exp Allergy. 2009 Jun;39(6):788-97
pubmed: 19302249
Respir Med. 2009 Nov;103(11):1633-42
pubmed: 19619998
J Allergy Clin Immunol. 2009 Dec;124(6):1210-6
pubmed: 19910033
Curr Med Res Opin. 2010 Jun;26(6):1285-93
pubmed: 20377320
Respir Med. 2010 Oct;104(10):1410-6
pubmed: 20483574
Chest. 2011 Jan;139(1):28-35
pubmed: 20688929
Rhinology. 2010 Sep;48(3):318-24
pubmed: 21038023
Ann Allergy Asthma Immunol. 2010 Nov;105(5):376-81
pubmed: 21055664
Curr Med Res Opin. 2011 Jan;27(1):163-9
pubmed: 21121874
N Engl J Med. 2011 Mar 17;364(11):1005-15
pubmed: 21410369
J Allergy Clin Immunol. 2011 Jun;127(6):1622-4
pubmed: 21546071
J Allergy Clin Immunol. 2012 Apr;129(4):983-9.e6
pubmed: 22365654
Arch Dis Child. 2012 Jul;97(7):604-9
pubmed: 22685051
Rhinol Suppl. 2012 Mar;23:3 p preceding table of contents, 1-298
pubmed: 22764607
Eur Respir J. 2013 Nov;42(5):1224-33
pubmed: 23520319
J Allergy Clin Immunol. 2013 Dec;132(6):1368-74
pubmed: 24176117
Cochrane Database Syst Rev. 2014 Jan 13;(1):CD003559
pubmed: 24414989
Respir Med. 2014 Apr;108(4):571-6
pubmed: 24565601
J Allergy Clin Immunol. 2014 Sep;134(3):560-567.e4
pubmed: 24679845
Allergy. 2014 Aug;69(8):1008-25
pubmed: 24909706
World Allergy Organ J. 2014 Jul 29;7(1):17
pubmed: 25097719
Gastroenterology. 2014 Dec;147(6):1255-66.e21
pubmed: 25160980
J Allergy Clin Immunol. 2015 Jan;135(1):289
pubmed: 25441294
J Invest Dermatol. 2015 Jan;135(1):13-15
pubmed: 25501377
J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):162-6
pubmed: 25609342
Curr Opin Allergy Clin Immunol. 2015 Jun;15(3):267-71
pubmed: 25899697
Eur Respir J. 2015 Sep;46(3):856-9
pubmed: 26022964
Clin Rev Allergy Immunol. 2016 Feb;50(1):84-96
pubmed: 26048266
J Allergy Clin Immunol. 2015 Jun;135(6):1519-28.e8
pubmed: 26051952
Ital J Pediatr. 2016 Jan 22;42:9
pubmed: 26796331
Pediatr Allergy Immunol. 2016 Aug;27(5):544-6
pubmed: 27003835
Respir Med. 2017 Sep;130:55-60
pubmed: 29206634
Curr Respir Med Rev. 2017 Mar;13(1):36-42
pubmed: 29213221